Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Esquire Financial Holdings, Inc is a banks-regional business based in the US. Esquire Financial shares (ESQ) are listed on the NASDAQ and all prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | USD$10.83 - USD$26.79 |
---|---|
50-day moving average | USD$22.3862 |
200-day moving average | USD$18.5532 |
Wall St. target price | USD$29 |
PE ratio | 13.5455 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$1.65 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Esquire Financial stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Esquire Financial's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Esquire Financial's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Esquire Financial shares trade at around 14x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Revenue TTM | USD$45.8 million |
---|---|
Operating margin TTM | 37.45% |
Gross profit TTM | USD$45.8 million |
Return on assets TTM | 1.46% |
Return on equity TTM | 10.64% |
Profit margin | 27.53% |
Book value | $16.733 |
Market capitalisation | USD$174.2 million |
TTM: trailing 12 months
There are currently 82,581 Esquire Financial shares held short by investors – that's known as Esquire Financial's "short interest". This figure is 6.1% up from 77,843 last month.
There are a few different ways that this level of interest in shorting Esquire Financial shares can be evaluated.
Esquire Financial's "short interest ratio" (SIR) is the quantity of Esquire Financial shares currently shorted divided by the average quantity of Esquire Financial shares traded daily (recently around 29493.214285714). Esquire Financial's SIR currently stands at 2.8. In other words for every 100,000 Esquire Financial shares traded daily on the market, roughly 2800 shares are currently held short.
However Esquire Financial's short interest can also be evaluated against the total number of Esquire Financial shares, or, against the total number of tradable Esquire Financial shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Esquire Financial's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Esquire Financial shares in existence, roughly 10 shares are currently held short) or 0.0121% of the tradable shares (for every 100,000 tradable Esquire Financial shares, roughly 12 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Esquire Financial.
Find out more about how you can short Esquire Financial stock.
We're not expecting Esquire Financial to pay a dividend over the next 12 months.
Over the last 12 months, Esquire Financial's shares have ranged in value from as little as $10.83 up to $26.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Esquire Financial's is 1.199. This would suggest that Esquire Financial's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Esquire Financial Holdings, Inc. operates as the bank holding company for Esquire Bank, National Association that provides commercial banking products and services to legal and small business communities, and commercial and retail customers in the United States. The company offers checking, savings, money market, and time deposits, as well as certificates of deposit. It also provides commercial loans, including short-term financing for inventory, receivables, the purchase of supplies, or other operating needs arising during the normal course of business, as well as loans to its qualified merchant customers; commercial lines of credit; consumer loans consisting of post-settlement consumer and structured settlement loans to plaintiffs and claimants, as well as loans to individuals for debt consolidation, medical expenses, living expenses, payment of outstanding bills, or other consumer needs; and real estate loans, such as multifamily, 1-4 family residential, commercial real estate, and construction loans, as well as merchant services. As of December 31, 2019, the company operated a branch in Jericho, New York; and an administrative office in Boca Raton, Florida. Esquire Financial Holdings, Inc. was founded in 2006 and is headquartered in Jericho, New York.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.